Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: Evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 1012-1021

  Zhuang, Luning ^a,b   He, Yang ^c   Xia, Huiming ^b   Liu, Yajun ^b   Sy, Sherwin K B ^a,d   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; EVALUATION STUDY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PSEUDOMONAS AERUGINOSA; ADVERSE EFFECTS; ALGORITHM; BACTERIAL INFECTIONS; COMPLICATION; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; MICROBIAL SENSITIVITY TEST; THEORETICAL MODEL;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; GENTAMICINS; HUMANS; KIDNEY FAILURE, CHRONIC; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; PSEUDOMONAS AERUGINOSA; RENAL DIALYSIS;

EID: 84964329777     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv428     Document Type: Article

References (29)

1. Kong X, Wen JQ, Qi RF et al. Diffuse interstitial brain edema in patients with end-stage renal disease undergoing hemodialysis: a tract-based spatial statistics study. Medicine (Baltimore) 2014; 93: e313.
2. Gupta V, Yassin MH. Infection and hemodialysis access: an updated review. Infect Disord Drug Targets 2013; 13: 196-205.
3. Begg EJ, Barclay ML. Aminoglycosides-50 years on. Br J Clin Pharmacol 1995; 39: 597-603.
4. Sowinski KM, Magner SJ, Lucksiri A et al. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 2008; 3: 355-61.
5. Teigen MM, Duffull S, Dang L et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 2006; 46: 1259-67.
6. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9.
7. O'Shea S, Duffull S, Johnson DW. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? Semin Dial 2009; 22: 225-30.
8. Sy SK, Derendorf H. Pharmacometrics in bacterial infections. In: Applied Pharmacometrics. Springer, New York, 2014; 229-58.
9. Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011; 55: 4619-30.
10. Zhuang L, Sy SK, Xia H et al. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semimechanistic pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents 2015; 45: 151-60.
11. TreyaprasertW, Schmidt S, Rand KH et al. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents 2007; 29: 263-70.
12. Lorentzen H, Kallehave F, Kolmos HJ et al. Gentamicin concentrations in human subcutaneous tissue. Antimicrob Agents Chemother 1996; 40: 1785-9.
13. Gordon RC, Regamey C, Kirby WM. Serum protein binding of the aminoglycoside antibiotics. Antimicrob Agents Chemother 1972; 2: 214-6.
14. Tam VH, Kabbara S, Vo G et al. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 2626-31.
15. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999; 16: 176-85.
16. Sy SK, Wang X, Derendorf H. Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics. In: Applied Pharmacometrics. Springer, New York, 2015; 1-64.
17. Barbour AM, Schmidt S, Zhuang L et al. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches. Int J Antimicrob Agents 2014; 43: 60-7.
18. Li Y, Xia H, Bai F et al. Identification of a new gene PA5017 involved in flagella-mediated motility, chemotaxis and biofilm formation in Pseudomonas aeruginosa. FEMS Microbiol Lett 2007; 272: 188-95.
19. Tseng BS, Zhang W, Harrison JJ et al. The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin. Environ Microbiol 2013; 15: 2865-78.
20. Matsuo H, Hayashi J, Ono K et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother 1997; 41: 2597-601.
21. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997; 24: 810-5.
22. Plajer SM, Chin PK, Vella-Brincat JW et al. Gentamicin and renal function: lessons from 15 years' experience of a pharmacokinetic service for extended interval dosing of gentamicin. Ther Drug Monit 2015; 37: 98-103.
23. MacGowan AP, Bedford KA, Blundell E et al. The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy. J Antimicrob Chemother 1994; 34: 809-12.
24. Medellin-Garibay SE, Rueda-Naharro A, Pena-Cabia S et al. Population pharmacokinetics of gentamicin and dosing optimization for infants. Antimicrob Agents Chemother 2015; 59: 482-9.
25. Rosario MC, Thomson AH, Jodrell DI et al. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998; 46: 229-36.
26. Bauer LA. The aminoglycoside antibiotics. In: Applied Clinical Pharmacokinetics. McGraw-Hill, New York, 2000; 97-298.
27. Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-64.
28. Mohamed AF, Nielsen EI, Cars O et al. Pharmacokineticpharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 2012; 56: 179-88.
29. Radivoyevitch T, Siranart N, Hlatky L et al. Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example. AAPS J 2015; 17: 447-56.